Impact of SARS-CoV-2 infection on patients with systemic lupus erythematosus in England prior to vaccination: a retrospective observational cohort study

被引:0
作者
Rabe, Adrian Paul J. [1 ,2 ]
Loke, Wei Jie [3 ]
Kalyani, Rubana N. [4 ]
Tummala, Raj [4 ]
Stirnadel-Farrant, Heide A. [5 ]
Were, John [6 ]
Winthrop, Kevin L. [7 ]
机构
[1] AstraZeneca, BioPharmaceut Med, Cambridge, England
[2] Imperial Coll London, Primary Care & Publ Hlth, London, England
[3] East & North Hertfordshire NHS Trust, Lister Hosp, Stevenage, Herts, England
[4] AstraZeneca US, BioPharmaceut R&D, Gaithersburg, MD USA
[5] AstraZeneca, Oncol Business Unit, Global Med Affairs, Cambridge, England
[6] Hlth IQ Ltd, Res Dept, London, England
[7] Oregon Hlth & Sci Univ, Dept Infect Dis, Portland, OR USA
来源
BMJ OPEN | 2023年 / 13卷 / 11期
关键词
COVID-19; HEALTH ECONOMICS; RHEUMATOLOGY; GENERAL MEDICINE (see Internal Medicine); INFECTIOUS DISEASES; PUBLIC HEALTH; COVID-19; DISEASE;
D O I
10.1136/bmjopen-2022-071072
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives Determine the prevaccination healthcare impact of COVID-19 in patients with systemic lupus erythematosus (SLE) in England. Design Retrospective cohort study of adult patients with SLE from 1 May to 31 October 2020. Setting Clinical Practice Research Datalink (CPRD) Aurum and Hospital Episode Statistics (HES) databases from general practitioners across England combining primary care and other health-related data. Participants Overall, 6145 adults with confirmed SLE diagnosis >= 1year prior to 1 May 2020 were included. Most patients were women (91.0%), white (67.1%), and diagnosed with SLE at age <50 (70.8%). Patients were excluded if they had a COVID-19 diagnosis before 1 May 2020. Primary and secondary outcome measures Demographics and clinical characteristics were compared. COVID-19 severity was determined by patient care required and procedure/diagnosis codes. COVID-19 cumulative incidence, hospitalisation rates, lengths of stay and mortality rates were determined and stratified by SLE and COVID-19 severity. Results Of 6145 patients, 3927 had mild, 1288 moderate and 930 severe SLE at baseline. The majority of patients with moderate to severe SLE were on oral corticosteroids and antimalarial treatments. Overall, 54/6145 (0.88%) patients with SLE acquired and were diagnosed with COVID-19, with 45 classified as mild, 6 moderate and 3 severe COVID-19. Cumulative incidence was higher in patients with severe SLE (1.4%) compared with patients classified as mild (0.8%) or moderate (0.8%). Ten COVID-19-specific hospital admissions occurred (n=6 moderate; n=4 severe). Regardless of COVID-19 status, hospital admission rates and length of stay increased with SLE severity. Of 54 patients with SLE diagnosed with COVID-19, 1 (1.9%) COVID-19-related death was recorded in a patient with both severe SLE and severe COVID-19. Conclusions SLE severity did not appear to impact COVID-19 outcomes in this study. The COVID-19 pandemic is evolving and follow-up studies are needed to understand the relationship between COVID-19 and SLE.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Analysis of related factors for systemic lupus erythematosus flare after SARS-Cov-2 infection: A retrospective cohort study
    Li, Qian
    Zhao, Jun-Kang
    Zhang, Jun-Yan
    Li, Rong
    Zhao, Li
    Su, Ya-Zhen
    Liu, Yang
    Xu, Ke
    Zhang, Li-Yun
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2025, 28 (01)
  • [2] Impact of prior SARS-CoV-2 infection on incidence of hospitalization and adverse events following mRNA SARS-CoV-2 vaccination: A nationwide, retrospective cohort study
    Li, Lucy L.
    Zheng, Chunlei
    La, Jennifer
    Do, Nhan, V
    Monach, Paul A.
    Strymish, Judith M.
    Fillmore, Nathanael R.
    Branch-Elliman, Westyn
    VACCINE, 2022, 40 (08) : 1082 - 1089
  • [3] SARS-CoV-2 and Systemic Lupus Erythematosus
    Aikaterini Thanou
    Amr H. Sawalha
    Current Rheumatology Reports, 2021, 23
  • [4] SARS-CoV-2 and Systemic Lupus Erythematosus
    Thanou, Aikaterini
    Sawalha, Amr H.
    CURRENT RHEUMATOLOGY REPORTS, 2021, 23 (02)
  • [5] Impact of first wave of SARS-CoV-2 infection in patients with Systemic Lupus Erythematosus: Weighting the risk of infection and flare
    Zucchi, Dina
    Tani, Chiara
    Elefante, Elena
    Stagnaro, Chiara
    Carli, Linda
    Signorini, Viola
    Ferro, Francesco
    Trentin, Francesca
    Fulvio, Giovanni
    Cardelli, Chiara
    Di Battista, Marco
    Governato, Gianmaria
    Figliomeni, Antonio
    Mosca, Marta
    PLOS ONE, 2021, 16 (01):
  • [6] The impact of SARS-CoV-2 coronavirus infection in patients with systemic lupus erythematosus from a single center in Catalonia
    Espinosa, Gerard
    Prieto-Gonzalez, Sergio
    Llevadot, Mireia
    Marco-Hernandez, Javier
    Martinez-Artuna, Antonio
    Perez-Isidro, Albert
    Rife, Elia
    Cervera, Ricard
    CLINICAL RHEUMATOLOGY, 2021, 40 (05) : 2057 - 2063
  • [7] The impact of SARS-CoV-2 coronavirus infection in patients with systemic lupus erythematosus from a single center in Catalonia
    Gerard Espinosa
    Sergio Prieto-González
    Mireia Llevadot
    Javier Marco-Hernández
    Antonio Martínez-Artuña
    Albert Pérez-Isidro
    Elia Rifé
    Ricard Cervera
    Clinical Rheumatology, 2021, 40 : 2057 - 2063
  • [8] The impact of SARS-CoV-2 infection and vaccination on inflammatory arthritis: a cohort study
    Striani, Giovanni
    Hoxha, Ariela
    Lorenzin, Mariagrazia
    Cozzi, Giacomo
    Scagnellato, Laura
    Vangelista, Tatiana
    Frizzera, Francesca
    De Sandre, Pierino
    Simioni, Paolo
    Doria, Andrea
    Ramonda, Roberta
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [9] Clinical and peculiar immunological manifestations of SARS-CoV-2 infection in systemic lupus erythematosus patients
    Schioppo, Tommaso
    Argolini, Lorenza Maria
    Sciascia, Savino
    Pregnolato, Francesca
    Tamborini, Francesco
    Miraglia, Paolo
    Roccatello, Dario
    Sinico, Renato Alberto
    Caporali, Roberto
    Moroni, Gabriella
    Gerosa, Maria
    RHEUMATOLOGY, 2022, 61 (05) : 1928 - 1935
  • [10] Risk of disease flares after SARS-CoV-2 mRNA vaccination in patients with systemic lupus erythematosus
    Kikuchi, Jun
    Kondo, Yasushi
    Kojima, Shuichiro
    Kasai, Shiho
    Sakai, Yuma
    Takeshita, Masaru
    Hiramoto, Kazuoto
    Saito, Shuntaro
    Fukui, Hiroyuki
    Hanaoka, Hironari
    Suzuki, Katsuya
    Kaneko, Yuko
    IMMUNOLOGICAL MEDICINE, 2024, : 76 - 84